Flerie Invest (Flerie AB) is a publicly traded life-science investment company headquartered in Stockholm, Sweden, that invests in and builds pioneering pharmaceutical and biotech companies. The firm differentiates itself by using its network, expertise, and resources to advance portfolio companies' pipelines from early development through to commercialisation, with a mission to make a positive impact on health and well-being. Flerie's portfolio includes companies such as Atrogi, Egetis Therapeutics, Xspray Pharma, Empros Pharma, Lipum, EpiEndo, and Symcel. The firm maintains a hands-on approach, providing operational support and strategic guidance through its experienced team of advisors and venture partners, many of whom hold board positions across portfolio companies. Flerie also operates NorthX Biologics, a CDMO established after acquiring a manufacturing facility from Charles River.
Profile auto-generated from public sources — details unverified.
Ted Fjällman
Chief Executive Officer
Cecilia Stureborg von Schéele
Chief Financial Officer
Mark Quick
Partner
Thomas Eldered
Executive Chairman
José Ochoa
Venture Partner
Arvid Söderhäll
Venture Partner
Carl-Johan Spak
Senior Advisor
Fredrik Lehmann
Senior Advisor
Michaela Gertz
Head of Investor Relations
Paula Andersson
Investor Relations and Operations Manager